Regeneron Pharmaceuticals, Inc. (REGN) stock
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/308% above fair value
$951.19−8.22 (-0.86%)
Close on Nov 12, 2026Market cap $98.40BP/E 21.0Yield –
Regeneron Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Regeneron Pharmaceuticals's gross margin for the twelve months ending Mar 31, 2018 was 96.5%. For fiscal 2019 it was 93.9%, against 95.4% the year before. The highest annual figure on record is 99.6% in fiscal 2008.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | 93.9% | −1.5 |
| FY2018 | Dec 31, 2018 | 95.4% | −1.2 |
| FY2017 | Dec 31, 2017 | 96.6% | +0.6 |
| FY2016 | Dec 31, 2016 | 96.0% | +1.9 |
| FY2015 | Dec 31, 2015 | 94.1% | −1.3 |
| FY2014 | Dec 31, 2014 | 95.4% | +1.0 |
| FY2013 | Dec 31, 2013 | 94.4% | +0.5 |
| FY2012 | Dec 31, 2012 | 93.9% | −5.1 |
| FY2011 | Dec 31, 2011 | 99.1% | −0.5 |
| FY2010 | Dec 31, 2010 | 99.5% | −0.0 |
| FY2009 | Dec 31, 2009 | 99.6% | −0.1 |
| FY2008 | Dec 31, 2008 | 99.6% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2018 | Mar 31, 2018 | 95.4% | +0.1 |
| Q4 FY2017 | Dec 31, 2017 | 96.7% | +0.3 |
| Q3 FY2017 | Sep 30, 2017 | 96.9% | – |
| Q2 FY2017 | Jun 30, 2017 | 97.1% | – |
| Q1 FY2017 | Mar 31, 2017 | 95.4% | – |
| Q4 FY2016 | Dec 31, 2016 | 96.4% | – |
See a number that looks wrong?